NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integra investors who were adversely affected by alleged securities fraud between March 11, 2019 and May 22, 2023. Follow the link below to get more information and be contacted by a member of our team:
IART investors may also contact Joseph E. Levi, Esq. via email at firstname.lastname@example.org or by telephone at (212) 363-7500.
CASE DETAILS: According to the complaint, defendants made false statements and/or concealed that Integra had failed to take sufficient measures to remediate the violations identified by the FDA in the November 2, 2018 Notice of Inspectional Observations on Form 483 (the “2018 Form 483”), the March 6, 2019 FDA issued warning letter (the “2019 Warning Letter”), and the November 12, 2021 FDA issued Form 483 (the “2021 Form 483”). As a result of those deficiencies, since March 2018, all products manufactured in the Boston Facility had the potential for higher-than-permitted levels of endotoxin and would need to be recalled. Moreover, the Company was not making progress towards obtaining its premarket approval (“PMA”) indication for SurgiMend, in part, because the manufacturing site that would produce the PMA product, the Boston Facility, was in continued violation of the FDA standards that Integra failed to rectify years after the initial notice of the violations and as a result the facility had to be shutdown to correct those ongoing deficiencies.
WHAT’S NEXT? If you suffered a loss in Integra during the relevant time frame, you have until November 13, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
- ICPT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders - September 27, 2023
- Propylene Carbonate Market revenue to surpass USD 470 Million by 2035, says Research Nester - September 27, 2023
- Spirulina Powder Market on Track to Achieve US$ 777.18 million by 2033 with a Resilient 6.4% CAGR | Future Market Insights - September 27, 2023